Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

• Published in: Blood Vol. 122; no. 7; pp. 1284 - 1292
• Main Authors: Höglund, Martin, Sandin, Fredrik, Hellström, Karin, Björeman, Mats, Björkholm, Magnus, Brune, Mats, Dreimane, Arta, Ekblom, Marja, Lehmann, Sören, Ljungman, Per, Malm, Claes, Markevärn, Berit, Myhr-Eriksson, Kristina, Ohm, Lotta, Olsson-Strömberg, Ulla, Själander, Anders, Wadenvik, Hans, Simonsson, Bengt, Stenke, Leif, Richter, Johan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.08.2013; American Society of Hematology
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Clinical Medicine; Female; Follow-Up Studies; Hematologi; Hematology; Humans; Klinisk medicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Male; Medical and Health Sciences; MEDICIN; Medicin och hälsovetenskap; MEDICINE; Middle Aged; Myeloid Neoplasia; Prognosis; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Registries - statistics & numerical data; Sex Factors; Survival Rate; Sweden - epidemiology; Young Adult; Sweden
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2013-04-495598

Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to compile population-based information. This report is based on registry data from 2002 to 2010, when a total of 779 patients (425 men, 354 women; median age, 60 years) were diagnosed with CML (93% chronic, 5% accelerated, and 2% blastic phase) corresponding to an annual incidence of 0.9/100 000. In 2002, approximately half of the patients received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009. With a median follow-up of 61 months, the relative survival at 5 years was close to 1.0 for patients younger than 60 years and 0.9 for those aged 60 to 80 years, but only 0.6 for those older than 80 years. At 12 months, 3% had progressed to accelerated or blastic phase. Sokal, but not European Treatment and Outcome Study, high-risk scores were significantly linked to inferior overall and relative survival. Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival. •Patients up to age 70 years with CML treated within a decentralized health care setting had a relative survival close to 1.0.•Sokal, but not EUTOS, score at diagnosis predicted overall and relative survival in a population-based cohort of patients with CML.